Naslov
Clinical and Economic Consequences of the Pharmacological Hypoglycemic Treatment of Type 2 Diabetes in Croatia

Autori
Šarić, Tereza ; Benković, Vanesa ; Poljičanin, Tamara ; Šekerija, Mario

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
ISPOR 13th Annual European Congress - Research Abstracts ; Value In Health ; 13(7) / - , 2010, A301-A301

Skup
ISPOR 13th Annual European Congress - Health Technology Assessment: A European Collaboration

Mjesto i datum
Prag, Češka Republika, 06.11.2010. - 09.11.2010

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
diabetes mellitus; pharmacological therapy; economic consequences

Sažetak
OBJECTIVES: Diabetes mellitus type 2 (T2DM) is a chronically progressive disease and the treatment must be selected according to the pathophysiological phase of the disease at the time the treatment is begun. The Croatian public diabetology sector takes care of approximately 150, 000 adults treated with oral hypoglycemic agents (OHA) alone or in combination with insulin. Our objective was assessment of the clinical and economic consequences of OHA treatment in T2DM from a Croatian healthcare system perspective. METHODS: The target population defined for the study were diabetic patients treated with OHA alone. Medication consumption was quantified by using Pharmis and CroDiab data. A clinical expert panel provided resource-use information not available in published literature or health care databases. RESULTS: Current consumption data is showing that 62.8% patients are using OHA as monotherapy. Within this group, majority is using either biguanides or sulphonylureas. Patients treated with sulphonylureas are represented with almost the same percentage as those treated with biguanides (25% vs. 29%). Combination of two OHA is used in 34.2% while 3% of patients are treated by triple therapy. The most often choice in dual therapy is combination of biguanides and sulphonylureas while biguanides, sulphonylureas and thiazolidinediones in combination as the most favourable treatment option in triple therapy. Biguanides are used as a one of OHA in 61% of patients. CONCLUSIONS: Considering current clinical guidelines, lifetime benefits of biguanides and facts that they are low-cost agent, relatively small proportion of T2DM patients are treated with this agent in Croatia. Findings of this investigation revealed real life pattern of T2DM treatment, which enables directing in better treating and more cost effective management in Croatia.

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita

POVEZANOST RADA